Pharmaceutical

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 

Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.

Oct 22, 2024 - 04:00
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 
Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.
Read the original article

Tags:

Previous Article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Next Article

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year

STAT+: Nimbus Therapeutics raises $210 million in one o...

Sep 6, 2023

Smoking impairs immune response, even after quitting, new study says

Smoking impairs immune response, even after quitting, n...

Feb 15, 2024

Boehringer Ingelheim advances weight loss drug to Phase III trials

Boehringer Ingelheim advances weight loss drug to Phase...

Aug 18, 2023